Dave Weisman

Why Some People Thrive on Four Hours of Sleep Short sleepers, who make up less than one per cent of the population, spend significantly less time snoozing without any apparent health consequences.

Short sleepers, who make up less than one per cent of the population, spend significantly less than eight hours snoozing without any apparent health consequences. What can these rare individuals teach us about our relationship with rest? newyorkermag.visitlink.me/WQhwQk

isn’t one locked down in a quarantine?

A republic, the right to free speech, invented by geniuses, run by idiots.

P hacking prospectively.

The timeline: HHS/Jr no longer recommend universal HBV vax, THEN funded a trial to study the effects of that recommendation.

Was thinking just clinical use.

Covid only revealed the real problem: anti-science Movements.

I was told that not a single Downs patient has been treated with AATs. Eventually this will happen, but it's been 2 years!

Turned into reality.

Read this if you are into Alzheimer's disease. It will help reframe your mind.

Wow, GREAT thread. Thank you. Given that we see APOE44 in 1-2% of the population and about 15% in AD trials, I concur with the risk being about 6 fold higher. And LOVE what you said about relative risk to APOE3 vs2.

This is a REALLY interesting topic, want to present it to American docs?

The Rise of the Self-Serve Blood Test

"Function says it is not a medical provider." So what IS it? www.nytimes.com/2026/01/08/w...

Thanks for this. Imagine being @drsforamerica.bsky.social and opposing the approval.

Dungeon Crawler Carl. The other answers are wrong.

Seriously, its a vacation from the madness. Bonus for the audible, great performance by Jeff Hayes.

Onwards!

Punk rock girl came on Pandora. How in the world had I not uploaded that song before? I’m questioning other decisions I’ve made.

I've already seen the con, thanks to Bredesen. OTOH, it also decreases "door to needle" times for the anti-amyloid therapies.

Two AD failures in one day. Novo's semaglutide and the anti-tau mab posdinemab. Sad day for the field.

GLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease | NeurologyLive - Clinical Neurology News and Neurology Expert Insights Results from the EVOKE and EVOKE+ phase 3 studies reported that oral semaglutide did not significantly reduce clinical progression in patients with early symptomatic Alzheimer disease.

The Novo GLP trial failed in AD. Beware lack of mechanism and loss for repurposed drugs.

www.neurologylive.com/view/glp-1-s...

Sad. These men and women fought for better.

"Irrespective of one's stance on the clinical efficacy of lecanemab.." What does this even mean? We have the data that shows the efficacy.

Earned that poutine.

I love Canada. Got to speak at the CAGP-CCSMH 2025 Annual Scientific Meeting.

Wait till they find out how doctors used to treat syphilis.

Intranasal Oxytocin for Managing Agitation in a Patient of Mixed Dementia With Multiple Pathologies, Particularly With a History of Repetitive Head Injuries - Naresh Jadav, Sümeyye Kuş, James Ellison,... Background Agitation is common in persons living with dementia (major neurocognitive disorder) and worsens with disease progression. Brexpiprazole is the sole F...

Weird case of Oxytocin helping with agitation.

journals.sagepub.com/doi/10.1177/...

Go Sid!

He’s almost moving from a werewolf to aware wolf.

This will be the first winner of the Ig-Nobel and the Nobel.

Wrapping up Vermont riding.

Join me in burning out more doctors.